Explore how evolving treatment strategies and biomarkers are transforming the management of HER2-positive breast cancer in clinical practice.

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes. In a presentation at the recent 42 nd Annual ...

ENHERTU Plus Pertuzumab Type II Variation Application Validated in EU as First-Line Treatment of Patients with HER2 Positive ...

Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its founding members. | Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its ...

So this looked at patients with ER-positive, HER2-Positive metastatic breast cancer who had received induction chemotherapy ...

What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...

"Therapy for small, node-negative, HER2-positive breast cancer can be challenging due to the risk of overtreatment. Our study can help assess outcomes of patients according to specific tumor sizes and ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...